Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

February 28, 2014

Conditions
Huntington Disease
Interventions
DRUG

PBT2

250mg capsules administered orally once per day for 26 weeks

DRUG

PBT2

100mg capsules administered orally once per day for 26 weeks

DRUG

Placebo

Matching capsules administered orally once per day for 26 weeks

Trial Locations (19)

2145

Westmead Hospital, Sydney

3050

Royal Melbourne Hospital, Parkville

3101

University of Melbourne Normanby Unit - St Vincents/St Georges, Melbourne

3800

Calvary Health Care Bethlehem, Clayton

6008

Neurodegenerative Disorders Research, Perth

10032

Columbia University Medical Center, New York

12208

Albany Medical College, Albany

21201

University of Maryland School of Medicine, Baltimore

21287

Johns Hopkins University, Baltimore

33136

University of Miami, Miami

38163

University of Tennessee Health Science Center, Memphis

43210

Ohio State University Medical Center, Columbus

55427

Struthers Parkinson's Center, Golden Valley

63110

Washington University, St Louis

80113

Colorado Neurological Institute, Englewood

92161

University of California San Diego, San Diego

98034

Booth Gardner Parkinson's Care Center, Kirkland

06030

University of Connecticut Health Center, Farmington

02129

Massachusetts General Hospital East, Charlestown

Sponsors
All Listed Sponsors
lead

Prana Biotechnology Limited

INDUSTRY